Transition Bio Overview

  • Year Founded
  • 2020

Year Founded

  • Status
  • Private

  • Employees
  • 27

Employees

  • Latest Deal Type
  • Series A

  • Latest Deal Amount
  • $13.3M

  • Investors
  • 6

Transition Bio General Information

Description

Operator of a biotechnology company intended to build a hypothesis-free drug discovery and diagnostics platform for human health care advancement. The company harnesses droplet microfluidic approaches and protein biophysics platforms to characterize condensates with unprecedented precision, enabling medical practitioners to map condensates in molecular detail.

Contact Information

Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Corporate Office
  • 1 Mifflin Place
  • Suite 400
  • Cambridge, MA 02138
  • United States
Primary Industry
Discovery Tools (Healthcare)
Corporate Office
  • 1 Mifflin Place
  • Suite 400
  • Cambridge, MA 02138
  • United States

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Transition Bio Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
5. Early Stage VC (Series A) 24-Oct-2024 $13.3M Completed Clinical Trials - General
4. Early Stage VC Completed Clinical Trials - General
3. Early Stage VC (Series A) 02-Jun-2022 Completed Clinical Trials - General
2. Seed Round 01-Sep-2020 $9M $9M Completed Startup
1. University Spin-Out 16-Jul-2020 Completed Startup
To view Transition Bio’s complete valuation and funding history, request access »

Transition Bio Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion Price % Owned
Series A
Seed
To view Transition Bio’s complete cap table history, request access »

VC Exit Predictor

See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.

Opportunity Score

Calculated using Exit Type probabilities, the company’s stage, and PitchBook’s historical returns data.

Exit Type

Evaluates the likelihood of a successful exit for investors, and the most likely exit type.

Transition Bio Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Operator of a biotechnology company intended to build a hypothesis-free drug discovery and diagnostics platform for huma
Discovery Tools (Healthcare)
Cambridge, MA
27 As of 2025

Paris, France
 

San Francisco, CA
 
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Transition Bio Competitors (2)

One of Transition Bio’s 2 competitors is Owkin, a Venture Capital-Backed company based in Paris, France.

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Owkin Venture Capital-Backed Paris, France
Numerion Labs Venture Capital-Backed San Francisco, CA
You’re viewing 2 of 2 competitors. Get the full list »

Transition Bio Patents

Transition Bio Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
GB-202318929-D0 New compounds and methods Inactive 12-Dec-2023
EP-4805092-A1 New compounds and methods Pending 08-Nov-2023
WO-2025099451-A1 New compounds and methods Inactive 08-Nov-2023
EP-4771389-A1 High-throughput condensate modulator screen Pending 01-Sep-2023
WO-2025050003-A1 High-throughput condensate modulator screen Inactive 01-Sep-2023 C40B30/10
To view Transition Bio’s complete patent history, request access »

Transition Bio Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Transition Bio Investors (6)

Investor Name Investor Type Holding Investor Since Participating Rounds
Bristol-Myers Squibb Corporation Minority
Magnetic Ventures Venture Capital Minority
Northpond Ventures Venture Capital Minority
Taiho Ventures Corporate Venture Capital Minority
Lifeforce Capital Venture Capital Minority
You’re viewing 5 of 6 investors. Get the full list »

Transition Bio FAQs

  • When was Transition Bio founded?

    Transition Bio was founded in 2020.

  • Where is Transition Bio headquartered?

    Transition Bio is headquartered in Cambridge, MA.

  • What is the size of Transition Bio?

    Transition Bio has 27 total employees.

  • What industry is Transition Bio in?

    Transition Bio’s primary industry is Discovery Tools (Healthcare).

  • Is Transition Bio a private or public company?

    Transition Bio is a Private company.

  • What is the current valuation of Transition Bio?

    The current valuation of Transition Bio is .

  • What is Transition Bio’s current revenue?

    The current revenue for Transition Bio is .

  • How much funding has Transition Bio raised over time?

    Transition Bio has raised $76.5M.

  • Who are Transition Bio’s investors?

    Bristol-Myers Squibb, Magnetic Ventures, Northpond Ventures, Taiho Ventures, and Lifeforce Capital are 5 of 6 investors who have invested in Transition Bio.

  • Who are Transition Bio’s competitors?

    Owkin and Numerion Labs are competitors of Transition Bio.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process